Alkermes Reports Q3 2026 Results with Strong Proprietary Product Growth
Alkermes (ALKS) reported third-quarter revenues of $480.1 million, driven by a 31% year-over-year increase in proprietary product net sales totaling $417.3 million. This growth was fueled by the successful launch and adoption of LUMRYZ, which saw approximately 4,100 patients enrolled by quarter-end, alongside steady demand for established products like VIVITROL and ARISTADA. Despite revenue strength, GAAP net income declined to $16.3 million from $82.8 million in the prior year, reflecting higher R&D investments in the orexin development portfolio and increased SG&A expenses following the Avadel transaction. The company maintains a strong liquidity position with $787.6 million in cash and investments as of September 30, 2026.
Topics: pharmaceuticals product sales R&D spending revenue growth